Profile - To The Moon

katecathey

Posts · 4Posts · 4
Following · 0Following · 0
Followers · 0Followers · 0

- katecatheykatecathey
  ·2021-06-10
  What will be the target price? Thx
  Biogen stock rockets to 6-year high after Alzheimer's drug gets FDA OK
  Shares rally to second -biggest one-day percentage gain since they went public 30 years agoShares of
  Biogen stock rockets to 6-year high after Alzheimer's drug gets FDA OK
  252 Comment
  Like
  Share
  Report
- katecatheykatecathey
  ·2021-03-29
  If everything is growing, why is there a loss?
  UPDATE 1-China's Meituan reported quarterly loss as it expands into new area
  (Adds details) BEIJING, March 26 (Reuters) - Chinese food delivery company Meituan reported a l
  UPDATE 1-China's Meituan reported quarterly loss as it expands into new area
  186 Comment
  Like
  Share
  Report
No followers yet

Most Discussed

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"isCurrentUser":false,"userPageInfo":{"id":"3575723063292449","uuid":"3575723063292449","gmtCreate":1612659448975,"gmtModify":1704447503024,"name":"katecathey","pinyin":"katecathey","introduction":"","introductionEn":"","signature":"","avatar":"https://community-static.tradeup.com/news/7133ebe6b60cbc1d8ddd273929224d85","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":0,"headSize":21,"tweetSize":4,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"cbe1c45c584340f3bd9ae6c77e0e9981-2","templateUuid":"cbe1c45c584340f3bd9ae6c77e0e9981","name":"Academy Explorer","description":"20 lessons learned","bigImgUrl":"https://community-static.tradeup.com/news/63cc10a4789c3eaa019b225a55136cf9","smallImgUrl":"https://community-static.tradeup.com/news/b1f0cbf3ae1b0a4593ddb3434df74ce0","grayImgUrl":null,"redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.12.24","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":2006},{"badgeId":"1026c425416b44e0aac28c11a0848493-2","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Senior Tiger","description":"Join the tiger community for 1000 days","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.11.05","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"44212b71d0be4ec88898348dbe882e03-3","templateUuid":"44212b71d0be4ec88898348dbe882e03","name":"President Tiger","description":"The transaction amount of the securities account reaches $1,000,000","bigImgUrl":"https://static.tigerbbs.com/fbeac6bb240db7da8b972e5183d050ba","smallImgUrl":"https://static.tigerbbs.com/436cdf80292b99f0a992e78750ac4e3a","grayImgUrl":"https://static.tigerbbs.com/506a259a7b456f037592c3b23c779599","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.23","exceedPercentage":"93.56%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"7a9f168ff73447fe856ed6c938b61789-1","templateUuid":"7a9f168ff73447fe856ed6c938b61789","name":"Knowledgeable Investor","description":"Traded more than 10 stocks","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"972123088c9646f7b6091ae0662215be-3","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Legendary Trader","description":"Total number of securities or futures transactions reached 300","bigImgUrl":"https://static.tigerbbs.com/656db16598a0b8f21429e10d6c1cb033","smallImgUrl":"https://static.tigerbbs.com/03f10910d4dd9234f9b5702a3342193a","grayImgUrl":"https://static.tigerbbs.com/0c767e35268feb729d50d3fa9a386c5a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":"93.12%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":6,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":8,"crmLevelSwitch":1,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":183630225,"gmtCreate":1623327125867,"gmtModify":1704200938515,"author":{"id":"3575723063292449","authorId":"3575723063292449","name":"katecathey","avatar":"https://community-static.tradeup.com/news/7133ebe6b60cbc1d8ddd273929224d85","crmLevel":8,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3575723063292449","authorIdStr":"3575723063292449"},"themes":[],"htmlText":"What will be the target price? Thx","listText":"What will be the target price? Thx","text":"What will be the target price? Thx","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/183630225","repostId":"2141453253","repostType":4,"repost":{"id":"2141453253","kind":"highlight","weMediaInfo":{"introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"media_name":"Dow Jones","id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1623096780,"share":"https://ttm.financial/m/news/2141453253?lang=&edition=fundamental","pubTime":"2021-06-08 04:13","market":"us","language":"en","title":"Biogen stock rockets to 6-year high after Alzheimer's drug gets FDA OK","url":"https://stock-news.laohu8.com/highlight/detail?id=2141453253","media":"Dow Jones","summary":"Shares rally to second -biggest one-day percentage gain since they went public 30 years agoShares of","content":"<p>Shares rally to second -biggest <a href=\"https://laohu8.com/S/AONE\">one</a>-day percentage gain since they went public 30 years ago</p><p>Shares of Biogen Inc. rocketed to a six-year high in volatile trading Monday, as Wall Street analysts cheered the U.S. Food and Drug Administration's broad labeling that came with the approval of the biotechnology company's Alzheimer's drug.</p><p>The stock <a href=\"https://laohu8.com/S/BIIB\">$(BIIB)$</a> blasted $109.71, or 38.3% higher, to $395.85, the highest close since April 2015. The stock had been halted twice for volatility  during Monday's session, once at 10:44 a.m. Eastern and a second time at 1:37 p.m.</p><p>Trading volume spiked up to 17.7 million shares, compared with the full-day average over the past 30 days of about 1.0 million shares, according to FactSet.</p><p>Earlier Friday, the FDA approved Biogen's Aduhelm , also known as aducanumab, to treat Alzheimer's, the first drug to be approved that promises to actually slow the disease rather than just treat the symptoms.</p><p>Biogen investors were treated to the stock's biggest-ever <a href=\"https://laohu8.com/S/AONE.U\">one</a>-day price gain, and second-biggest one-day percentage gain since it went public in September 1991. The stock had shot up $108.62, or 44.0%, on Nov. 4, 2020, after the FDA said there was \"substantial evidence\"</p><p>\"Currently available options only treat symptoms of the disease; this treatment option is the first therapy to target and affect the underlying disease process of Alzheimer's,\" said Patrizia Cavazzoni, director of the FDA's Center for Drug Evaluation and Research. \"As we have learned from the fight against cancer, the accelerated approval pathway can bring therapies to patients faster while spurring more research an innovation.\"</p><p>As the FDA described, accelerated approval can be based on the drug's effect on a surrogate endpoint that is reasonably likely to predict a clinical benefit to patients, with \"a required post-approval trial\" to verify the drug provides that expected clinical benefit.</p><p>Bernstein analyst Aaron Gal said approval under accelerated pathway is a distinction without a difference. \"The pathway allows for approval based on surrogate market, rather than completed efficacy endpoint data,\" Gal wrote in a note to clients. \"As long as Biogen does not challenge the use of the path, which they obviously would not, the approval holds.\"</p><p>Evercore ISI's Umer Raffat noted that the option of Accelerated Approval was not discussed by the FDA's advisory committee. And as the drug has \"clearly shown\" in all trials to substantially reduce amyloid beta plaques, the \"reduction in plaques is reasonably likely to result in clinical benefit.\"</p><p>Regarding labeling, Bernstein's Gal said it is \"almost shockingly broad,\" as the label just said Aduhelm is indicated for the treatment of Alzheimer's disease.</p><p>\"Thus, the approved population is broader than the tested population (mild-moderate Alzheimer's patients),\" Gal wrote. \"There is also no restriction on treatment duration suggesting that patients can stay on treatment until either all plaque is removed or the patient progresses.\"</p><p>Evercore's Raffat concurred, saying the label reads very very broad. He indicated that investors could be relieved, as there was some concern that the target population might be limited, and/or require very frequent monitoring.</p><p>Although pricing is still unknown, the Institute of Clinical and Economic Review (ICER) said that due to the relatively small overall health gains demonstrated in Phase 3 clinical trials, the drug should be price no higher than $8,400 a year, as MarketWatch's Jaimy Lee reported .</p><p>Some analysts say Biogen could price the drug higher than that, even though that might potentially trigger a regulatory response.</p><p>Evercore's Raffat said his financial estimates on Biogen include an estimate of $10,000, while Bernstein's Gal said the pricing could end up \"much higher,\" possibly as high as more than $30,000.</p><p>Gal said Biogen has a long history of pricing drugs in the \"specialty\" range, and is less likely to fear a backlash. \"Biogen would justify the price by arguing the total system impact would be modest upfront and that it will use the money to provide substantial services to [Alzheimer's disease] patients,\" Gal wrote.</p><p>Biogen and Eisai Inc., the U.S. subsidiary of Japan-based Eisai Co. Ltd. (4523.TO), announced after Aduhelm's approval programs intended to support access for all qualified patients, including those from traditionally underserved populations.</p><p>Eisai's U.S.-listed shares skyrocketed 68.9% in afternoon trading, on track for a record close and the biggest one-day gain since it started trading in the U.S. in December 1995.</p><p>\"We are committed to access and health equity as top priorities and will continue working with multiple stakeholders with the goal of helping patients who may benefit from treatment obtain care as quickly as possible,\" said Alisha Alaimo, president of Biogen U.S.</p><p>Biogen's stock has now run up 61.7% year to date, while SPDR Health Care Select Sector exchange-traded fund <a href=\"https://laohu8.com/S/XLV\">$(XLV)$</a> has gained 8.0% and the S&amp;P 500 index  has advanced 12.5%.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Biogen stock rockets to 6-year high after Alzheimer's drug gets FDA OK</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiogen stock rockets to 6-year high after Alzheimer's drug gets FDA OK\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2021-06-08 04:13</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares rally to second -biggest <a href=\"https://laohu8.com/S/AONE\">one</a>-day percentage gain since they went public 30 years ago</p><p>Shares of Biogen Inc. rocketed to a six-year high in volatile trading Monday, as Wall Street analysts cheered the U.S. Food and Drug Administration's broad labeling that came with the approval of the biotechnology company's Alzheimer's drug.</p><p>The stock <a href=\"https://laohu8.com/S/BIIB\">$(BIIB)$</a> blasted $109.71, or 38.3% higher, to $395.85, the highest close since April 2015. The stock had been halted twice for volatility  during Monday's session, once at 10:44 a.m. Eastern and a second time at 1:37 p.m.</p><p>Trading volume spiked up to 17.7 million shares, compared with the full-day average over the past 30 days of about 1.0 million shares, according to FactSet.</p><p>Earlier Friday, the FDA approved Biogen's Aduhelm , also known as aducanumab, to treat Alzheimer's, the first drug to be approved that promises to actually slow the disease rather than just treat the symptoms.</p><p>Biogen investors were treated to the stock's biggest-ever <a href=\"https://laohu8.com/S/AONE.U\">one</a>-day price gain, and second-biggest one-day percentage gain since it went public in September 1991. The stock had shot up $108.62, or 44.0%, on Nov. 4, 2020, after the FDA said there was \"substantial evidence\"</p><p>\"Currently available options only treat symptoms of the disease; this treatment option is the first therapy to target and affect the underlying disease process of Alzheimer's,\" said Patrizia Cavazzoni, director of the FDA's Center for Drug Evaluation and Research. \"As we have learned from the fight against cancer, the accelerated approval pathway can bring therapies to patients faster while spurring more research an innovation.\"</p><p>As the FDA described, accelerated approval can be based on the drug's effect on a surrogate endpoint that is reasonably likely to predict a clinical benefit to patients, with \"a required post-approval trial\" to verify the drug provides that expected clinical benefit.</p><p>Bernstein analyst Aaron Gal said approval under accelerated pathway is a distinction without a difference. \"The pathway allows for approval based on surrogate market, rather than completed efficacy endpoint data,\" Gal wrote in a note to clients. \"As long as Biogen does not challenge the use of the path, which they obviously would not, the approval holds.\"</p><p>Evercore ISI's Umer Raffat noted that the option of Accelerated Approval was not discussed by the FDA's advisory committee. And as the drug has \"clearly shown\" in all trials to substantially reduce amyloid beta plaques, the \"reduction in plaques is reasonably likely to result in clinical benefit.\"</p><p>Regarding labeling, Bernstein's Gal said it is \"almost shockingly broad,\" as the label just said Aduhelm is indicated for the treatment of Alzheimer's disease.</p><p>\"Thus, the approved population is broader than the tested population (mild-moderate Alzheimer's patients),\" Gal wrote. \"There is also no restriction on treatment duration suggesting that patients can stay on treatment until either all plaque is removed or the patient progresses.\"</p><p>Evercore's Raffat concurred, saying the label reads very very broad. He indicated that investors could be relieved, as there was some concern that the target population might be limited, and/or require very frequent monitoring.</p><p>Although pricing is still unknown, the Institute of Clinical and Economic Review (ICER) said that due to the relatively small overall health gains demonstrated in Phase 3 clinical trials, the drug should be price no higher than $8,400 a year, as MarketWatch's Jaimy Lee reported .</p><p>Some analysts say Biogen could price the drug higher than that, even though that might potentially trigger a regulatory response.</p><p>Evercore's Raffat said his financial estimates on Biogen include an estimate of $10,000, while Bernstein's Gal said the pricing could end up \"much higher,\" possibly as high as more than $30,000.</p><p>Gal said Biogen has a long history of pricing drugs in the \"specialty\" range, and is less likely to fear a backlash. \"Biogen would justify the price by arguing the total system impact would be modest upfront and that it will use the money to provide substantial services to [Alzheimer's disease] patients,\" Gal wrote.</p><p>Biogen and Eisai Inc., the U.S. subsidiary of Japan-based Eisai Co. Ltd. (4523.TO), announced after Aduhelm's approval programs intended to support access for all qualified patients, including those from traditionally underserved populations.</p><p>Eisai's U.S.-listed shares skyrocketed 68.9% in afternoon trading, on track for a record close and the biggest one-day gain since it started trading in the U.S. in December 1995.</p><p>\"We are committed to access and health equity as top priorities and will continue working with multiple stakeholders with the goal of helping patients who may benefit from treatment obtain care as quickly as possible,\" said Alisha Alaimo, president of Biogen U.S.</p><p>Biogen's stock has now run up 61.7% year to date, while SPDR Health Care Select Sector exchange-traded fund <a href=\"https://laohu8.com/S/XLV\">$(XLV)$</a> has gained 8.0% and the S&amp;P 500 index  has advanced 12.5%.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BIIB":"渤健公司"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2141453253","content_text":"Shares rally to second -biggest one-day percentage gain since they went public 30 years agoShares of Biogen Inc. rocketed to a six-year high in volatile trading Monday, as Wall Street analysts cheered the U.S. Food and Drug Administration's broad labeling that came with the approval of the biotechnology company's Alzheimer's drug.The stock $(BIIB)$ blasted $109.71, or 38.3% higher, to $395.85, the highest close since April 2015. The stock had been halted twice for volatility  during Monday's session, once at 10:44 a.m. Eastern and a second time at 1:37 p.m.Trading volume spiked up to 17.7 million shares, compared with the full-day average over the past 30 days of about 1.0 million shares, according to FactSet.Earlier Friday, the FDA approved Biogen's Aduhelm , also known as aducanumab, to treat Alzheimer's, the first drug to be approved that promises to actually slow the disease rather than just treat the symptoms.Biogen investors were treated to the stock's biggest-ever one-day price gain, and second-biggest one-day percentage gain since it went public in September 1991. The stock had shot up $108.62, or 44.0%, on Nov. 4, 2020, after the FDA said there was \"substantial evidence\"\"Currently available options only treat symptoms of the disease; this treatment option is the first therapy to target and affect the underlying disease process of Alzheimer's,\" said Patrizia Cavazzoni, director of the FDA's Center for Drug Evaluation and Research. \"As we have learned from the fight against cancer, the accelerated approval pathway can bring therapies to patients faster while spurring more research an innovation.\"As the FDA described, accelerated approval can be based on the drug's effect on a surrogate endpoint that is reasonably likely to predict a clinical benefit to patients, with \"a required post-approval trial\" to verify the drug provides that expected clinical benefit.Bernstein analyst Aaron Gal said approval under accelerated pathway is a distinction without a difference. \"The pathway allows for approval based on surrogate market, rather than completed efficacy endpoint data,\" Gal wrote in a note to clients. \"As long as Biogen does not challenge the use of the path, which they obviously would not, the approval holds.\"Evercore ISI's Umer Raffat noted that the option of Accelerated Approval was not discussed by the FDA's advisory committee. And as the drug has \"clearly shown\" in all trials to substantially reduce amyloid beta plaques, the \"reduction in plaques is reasonably likely to result in clinical benefit.\"Regarding labeling, Bernstein's Gal said it is \"almost shockingly broad,\" as the label just said Aduhelm is indicated for the treatment of Alzheimer's disease.\"Thus, the approved population is broader than the tested population (mild-moderate Alzheimer's patients),\" Gal wrote. \"There is also no restriction on treatment duration suggesting that patients can stay on treatment until either all plaque is removed or the patient progresses.\"Evercore's Raffat concurred, saying the label reads very very broad. He indicated that investors could be relieved, as there was some concern that the target population might be limited, and/or require very frequent monitoring.Although pricing is still unknown, the Institute of Clinical and Economic Review (ICER) said that due to the relatively small overall health gains demonstrated in Phase 3 clinical trials, the drug should be price no higher than $8,400 a year, as MarketWatch's Jaimy Lee reported .Some analysts say Biogen could price the drug higher than that, even though that might potentially trigger a regulatory response.Evercore's Raffat said his financial estimates on Biogen include an estimate of $10,000, while Bernstein's Gal said the pricing could end up \"much higher,\" possibly as high as more than $30,000.Gal said Biogen has a long history of pricing drugs in the \"specialty\" range, and is less likely to fear a backlash. \"Biogen would justify the price by arguing the total system impact would be modest upfront and that it will use the money to provide substantial services to [Alzheimer's disease] patients,\" Gal wrote.Biogen and Eisai Inc., the U.S. subsidiary of Japan-based Eisai Co. Ltd. (4523.TO), announced after Aduhelm's approval programs intended to support access for all qualified patients, including those from traditionally underserved populations.Eisai's U.S.-listed shares skyrocketed 68.9% in afternoon trading, on track for a record close and the biggest one-day gain since it started trading in the U.S. in December 1995.\"We are committed to access and health equity as top priorities and will continue working with multiple stakeholders with the goal of helping patients who may benefit from treatment obtain care as quickly as possible,\" said Alisha Alaimo, president of Biogen U.S.Biogen's stock has now run up 61.7% year to date, while SPDR Health Care Select Sector exchange-traded fund $(XLV)$ has gained 8.0% and the S&P 500 index  has advanced 12.5%.","news_type":1},"isVote":1,"tweetType":1,"viewCount":252,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":352732347,"gmtCreate":1617003243389,"gmtModify":1704800667747,"author":{"id":"3575723063292449","authorId":"3575723063292449","name":"katecathey","avatar":"https://community-static.tradeup.com/news/7133ebe6b60cbc1d8ddd273929224d85","crmLevel":8,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3575723063292449","authorIdStr":"3575723063292449"},"themes":[],"htmlText":"If everything is growing, why is there a loss?&nbsp;","listText":"If everything is growing, why is there a loss?&nbsp;","text":"If everything is growing, why is there a loss?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/352732347","repostId":"2122262478","repostType":2,"repost":{"id":"2122262478","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1616750431,"share":"https://ttm.financial/m/news/2122262478?lang=&edition=fundamental","pubTime":"2021-03-26 17:20","market":"sh","language":"en","title":"UPDATE 1-China's Meituan reported quarterly loss as it expands into new area","url":"https://stock-news.laohu8.com/highlight/detail?id=2122262478","media":"Reuters","summary":"(Adds details)   BEIJING, March 26 (Reuters) - Chinese food delivery company Meituan    reported a l","content":"<html><body><p>(Adds details)</p><p>   BEIJING, March 26 (Reuters) - Chinese food delivery company Meituan    reported a loss on Friday for October-December after two consecutive quarters of profit, as it expanded into the community group-buying business that relies heavily on subsidies.</p><p>   It reported a loss of 2.24 billion yuan ($343 million) versus profit of 1.46 billion yuan in the same month a year earlier, the company said in a stock exchange filing.</p><p>   Meituan, whose services also include restaurant reviews and bike sharing, said total revenue rose 34.7% in October-December from a year earlier to 37.92 billion yuan ($5.80 billion). That compared with the 39.17 billion yuan average of 14 analyst estimates, IBES data from Refinitiv showed.</p><p>   Community group buying, which lets communities set up groups for bulk buying, is <a href=\"https://laohu8.com/S/AONE\">one</a> of Meituan's new initiatives that grew by 51.9% year-on-year in quarterly revenue to 9.24 billion yuan.</p><p>   Food delivery, which accounts for over half of Meituan's total revenue, posted revenue growth of 37.0% to 21.54 billion yuan. Its in-store, hotel and travel operation saw revenue growth of 12.2% to 7.14 billion yuan. ($1 = 6.5417 Chinese yuan renminbi)</p><p> (Reporting by Yingzhi Yang and Ryan Woo in Beijing; Editing by Miyoung Kim, Christopher Cushing and Toby Chopra)</p><p>((Yingzhi.Yang@thomsonreuters.com; +861056692133;))</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>UPDATE 1-China's Meituan reported quarterly loss as it expands into new area</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUPDATE 1-China's Meituan reported quarterly loss as it expands into new area\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-03-26 17:20</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p>(Adds details)</p><p>   BEIJING, March 26 (Reuters) - Chinese food delivery company Meituan    reported a loss on Friday for October-December after two consecutive quarters of profit, as it expanded into the community group-buying business that relies heavily on subsidies.</p><p>   It reported a loss of 2.24 billion yuan ($343 million) versus profit of 1.46 billion yuan in the same month a year earlier, the company said in a stock exchange filing.</p><p>   Meituan, whose services also include restaurant reviews and bike sharing, said total revenue rose 34.7% in October-December from a year earlier to 37.92 billion yuan ($5.80 billion). That compared with the 39.17 billion yuan average of 14 analyst estimates, IBES data from Refinitiv showed.</p><p>   Community group buying, which lets communities set up groups for bulk buying, is <a href=\"https://laohu8.com/S/AONE\">one</a> of Meituan's new initiatives that grew by 51.9% year-on-year in quarterly revenue to 9.24 billion yuan.</p><p>   Food delivery, which accounts for over half of Meituan's total revenue, posted revenue growth of 37.0% to 21.54 billion yuan. Its in-store, hotel and travel operation saw revenue growth of 12.2% to 7.14 billion yuan. ($1 = 6.5417 Chinese yuan renminbi)</p><p> (Reporting by Yingzhi Yang and Ryan Woo in Beijing; Editing by Miyoung Kim, Christopher Cushing and Toby Chopra)</p><p>((Yingzhi.Yang@thomsonreuters.com; +861056692133;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"03690":"美团-W","QNETCN":"纳斯达克中美互联网老虎指数"},"source_url":"http://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2122262478","content_text":"(Adds details)   BEIJING, March 26 (Reuters) - Chinese food delivery company Meituan    reported a loss on Friday for October-December after two consecutive quarters of profit, as it expanded into the community group-buying business that relies heavily on subsidies.   It reported a loss of 2.24 billion yuan ($343 million) versus profit of 1.46 billion yuan in the same month a year earlier, the company said in a stock exchange filing.   Meituan, whose services also include restaurant reviews and bike sharing, said total revenue rose 34.7% in October-December from a year earlier to 37.92 billion yuan ($5.80 billion). That compared with the 39.17 billion yuan average of 14 analyst estimates, IBES data from Refinitiv showed.   Community group buying, which lets communities set up groups for bulk buying, is one of Meituan's new initiatives that grew by 51.9% year-on-year in quarterly revenue to 9.24 billion yuan.   Food delivery, which accounts for over half of Meituan's total revenue, posted revenue growth of 37.0% to 21.54 billion yuan. Its in-store, hotel and travel operation saw revenue growth of 12.2% to 7.14 billion yuan. ($1 = 6.5417 Chinese yuan renminbi) (Reporting by Yingzhi Yang and Ryan Woo in Beijing; Editing by Miyoung Kim, Christopher Cushing and Toby Chopra)((Yingzhi.Yang@thomsonreuters.com; +861056692133;))","news_type":1},"isVote":1,"tweetType":1,"viewCount":186,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"defaultTab":"followers","isTTM":true}